Barry F Shearer from Scottsdale, AZ, age 71

Chemical Compounds As H-Pgds Inhibitors
view source
US Patent:

20200123152, Apr 23, 2020
Filed:

Jun 11, 2018
Appl. No.:

16/621927
Inventors:

- Brentford, Middlesex, GB
Barry George SHEARER - Collegeville PA, US
Mark Andrew YOUNGMAN - Collegeville PA, US
International Classification:

C07D 471/04
A61P 21/00
A61P 11/06
Abstract:

A compound of formula (I)wherein R, R, R, R, X, Y, and A are as defined herein.The compounds of the present invention are inhibitors of hematopoletic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

1,3 Di-Substituted Cyclobutane Or Azetidine Derivatives As Hematopoietic Prostaglandin D Synthase Inhibitors
view source
US Patent:

20190241554, Aug 8, 2019
Filed:

Oct 12, 2017
Appl. No.:

16/341113
Inventors:

- Brentford, Middlesex, GB
Yu GUO - Collegeville PA, US
Ashley Paul HANCOCK - Stevenage, GB
Christie SCHULTE - Collegeville PA, US
Barry George SHEARER - Collegeville PA, US
Emilie Despagnet SMITH - Apex NC, US
Eugene L. STEWART - Collegeville PA, US
Stephen Andrew THOMSON - Del Mar CA, US
International Classification:

C07D 417/14
A61P 11/06
A61P 21/00
C07D 417/12
C07D 277/64
C07D 471/04
C07D 215/24
C07D 239/72
C07C 235/40
Abstract:

A compound of formula (I)wherein R, R, R, R, Y, Y, a, X, and Z are as defined herein.The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.